Drug Approval | February 22, 2022
UK MHRA approves Marksans All in One oral solution
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
US $ 555,000 invested by Wavemaker Partners in pre-seed round
To be marketed by Strides Pharma Inc. in the US market
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Subscribe To Our Newsletter & Stay Updated
